Brooke Fruman

Authored Content

A recent Pear Therapeutics–Avalere survey of 30 payers and 10 employer self-insured groups identified numerous insights to direct future efforts for broader adoption and coverage of prescription digital therapeutics (PDTs).

New analysis from Avalere finds that in 2022 more Medicare Advantage plans will offer non-medical supplemental benefits, such as meals, nutrition, transportation, and in-home support services, at a $0 premium.

Prescription Digital Therapeutics (PDTs) are a growing and unique treatment modality that can provide expanded options for treatment to patients. As the landscape for these treatments develop across multiple therapeutic areas, challenges related to coverage, reimbursement, and access will need to be solved to advance broader adoption and utilization across key stakeholders.